|
||||||||||||||||||
Data:2009-12-12 2:34
Source: Hong Kong and Macao Information Author: Xue Wei
G Kang margin (600,557): The company has been among the ranks of major pharmaceutical company in Jiangsu Province. The current total production of 86 kinds of drugs, with nearly 10 Chinese government approved a new drug certificate, is listed as engineering technology center in Jiangsu Province, post-doctoral Technology Innovation Center. Company's leading product GuizhiFuling capsule by the National Science and Technology as a demonstration project of modernization of Chinese medicine recommended for the United States FDA clinical tests. Unit 2 on the market continued to climbed, volume and price with the good, investors may be properly recognized.Historical Information: G Kang margin (600,557): expected to continue a strong upward May 20, 2006
G Kang margin (600,557): The company has been among the ranks of major pharmaceutical company in Jiangsu Province. The current total production of 86 kinds of drugs, with nearly 10 Chinese government approved a new drug certificate, is listed as engineering technology center in Jiangsu Province, post-doctoral Technology Innovation Center. Company's leading product GuizhiFuling capsule by the National Science and Technology as a demonstration project of modernization of Chinese medicine recommended for the United States FDA clinical tests. Trend, the stock continued a strong upward may continue to hold.